# IpiNovyx Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ipinovyx-bio

- Industry: Biotechnology
- Headquarters: US
- Website: www.ipinovyxbio.com
- Total disclosed funding: $10M
- Latest round: Seed (Oct 5, 2021)
- Investors on record: 6

## About

IpiNovyx Bio, Inc. develops innovative therapies targeted at improving patient outcomes in critical areas of healthcare. Their work focuses on advancing drug candidates aimed at addressing unmet medical needs.Founded in 2021 in the United States, IpiNovyx Bio, Inc. specializes in biopharmaceutical development. The company has not reported any significant pivots in its strategy or operations. Its headquarters is located in an unspecified U.S. city. Franck Barrat serves as the Founder of the company, and Marc Appel is the CEO. In October 2021, IpiNovyx Bio, Inc. raised USD 10.000 mn in Seed funding, led by Viva BioInnovator, with participation from Alexandria Venture Investments, Eli Lilly & Company, Opaleye Management, Orange Grove Bio LLC, and Pathway Bioventures. This funding round represents the total amount raised by the company.IpiNovyx Bio, Inc. specializes in developing drug candidates to address critical medical conditions, focusing on areas with significant unmet needs. The company is advancing several lead drug candidates designed to improve patient outcomes and streamline treatment processes.The revenue model of IpiNovyx Bio, Inc. is primarily based on funding obtained through investment rounds as they develop their drug candidates. Their focus is on securing additional funding as they progress towards clinical trials, potentially generating revenue from partnerships and collaborations with larger pharmaceutical companies in the future.Following the recent Seed funding round in October 2021, IpiNovyx Bio, Inc. plans to utilize the USD 10.000 mn raised to advance its lead drug candidates towards first-in-human clinical studies. This includes preparing for the submission of their first investigational new drug (IND) application, with the aim to bring their innovations to market. The company is also focused on expanding its presence in the biopharmaceutical sector, targeting regions in North America and Europe for future collaborations and partnerships.

## Funding rounds

- Seed, Oct 5, 2021, $10M — Alexandria Venture Investments, Eli Lilly & Company, Opaleye Management, Viva BioInnovator, Orange Grove Bio LLC, Pathway Bioventures

## Investors

- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Seed
- Eli Lilly & Company — Seed
- Opaleye Management — Seed
- Viva BioInnovator (https://capitalatlas.ai/funds/viva-bioinnovator) — Seed
- Orange Grove Bio LLC — Seed
- Pathway Bioventures (https://capitalatlas.ai/funds/pathway-bioventures) — Seed